Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved]
While double-blinding is a crucial aspect of study design in an interventional clinical trial of medication for a disorder with subjective endpoints such as major depressive disorder, psychotherapy clinical trials, particularly cognitive-behavioral therapy trials, cannot be double-blinded. This pape...
Main Author: | Douglas Berger |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2015-08-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/4-638/v1 |
Similar Items
-
Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 2; referees: 2 approved]
by: Douglas Berger
Published: (2016-02-01) -
Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved]
by: Daniel F. Kripke
Published: (2018-11-01) -
Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 2; referees: 2 approved]
by: Daniel F. Kripke
Published: (2017-03-01) -
Understanding the role of serotonin in psychiatric diseases [version 1; referees: 3 approved]
by: Donatella Marazziti
Published: (2017-02-01) -
Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis [version 2; referees: 2 approved]
by: Mary A. Bitta, et al.
Published: (2017-06-01)